Source: Google NewsPublished on 2021-02-19
Related Articles:
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
- Inbrija Approved in US to Treat Off Periods in Parkinson’s Patients on Carbidopa/Levodopa January 10, 2019 The U.S. Food and Drug Administration has approved Inbrija (levodopa inhalation powder) for the treatment of Parkinson’s off periods in patients on a carbidopa/levodopa regimen. Acorda Therapeutics’ therapy is expected to be available by prescription in the first quarter of 2019. It will be distributed through a network of specialty pharmacies in the U.S. “Today’s approval of INBRIJA marks a…
- Monthly research review – October 2019 October 31, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions August 30, 2017 The U.S. Food and Drug Administration (FDA) will not process Acorda Therapeutics‘ marketing application for Inbrija (CVT-301), intended for the treatment of off-periods in Parkinson’s disease, until certain questions are answered. The FDA’s refusal to accept Acorda’s new drug application (NDA) for Inbrija wasn’t based on safety or efficacy concerns, but was related to the drug candidate’s manufacturing process. In a…
- Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
- Acorda Campaign Aims to Help Parkinson’s Patients Explain Their Challenges April 6, 2018 An initiative called Live Well. Do Tell is trying to help Parkinson’s patients do a better job of letting others know about the manifestations of their disease, particularly the return of movement problems during periods when standard treatments wear off. In addition to these off periods, many people are unaware of the non-movement symptoms of Parkinson’s, including depression or anxiety. One…
- Acorda Asks European Union to Approve Inbrija for Parkinson’s Off Periods March 28, 2018 Acorda Therapeutics has asked the European Medicines Agency to approve Inbrija (CVT-301) to reduce the periods when the standard Parkinson’s treatment carbidopa/levodopa is not working. Inbrija is a self-administered, inhaled levodopa therapy. Acorda developed it to reduce the time when standard levodopa treatment wears off — periods known as off times. Both movement and non-movement symptoms return during off times. About half of patients taking standard…
- FDA Accepts New Drug Application for Acorda’s Parkinson’s Therapy Inbrija February 23, 2018 The U.S. Food and Drug Administration has accepted Acorda Therapeutics’ New Drug Application for Inbrija (CVT-301) as a potential treatment for Parkinson’s disease. Accepting the application means the agency is ready to start its regulatory review of the therapy. It expects to make a decision by Oct. 5, 2018. Inbrija is an inhaled powder formulation of levodopa for the times when…
- Acorda Launches Online Tool to Help Parkinson’s Patients Discuss ‘Off Episodes’ October 25, 2019 To help Parkinson’s patients identify and discuss their “off episodes” — the return of disease symptoms — with healthcare providers, Acorda Therapeutics is offering a new online tool. Called the “Do Tell” Your Doctor Tool, the questionnaire is used to record such episodes, which can be hard to identify because these episodic symptoms and their frequency vary for each patient.…
- Acorda Therapeutics Announces Departure of President, International & General Counsel - Business Wire November 12, 2019 Acorda Therapeutics Announces Departure of President, International & General Counsel Business Wire
- #AAN2018- Inbrija Reduces Parkinson’s Off Periods, Phase 3 Trial Shows April 16, 2018 Inbrija reduces Parkinson’s symptoms when standard treatments wear off, and decreases the length of these off periods, a Phase 3 clinical trial shows. The therapy’s developer, Acorda Therapeutics, will present the results at the American Academy of Neurology annual meeting in Los Angeles, April 21-27. Parkinson’s News Today will be covering the conference. Acorda’s presentation will be at 4:54 p.m. Pacific time on Tuesday, April 24.…
- Parkinson's Disease News - Editor's Picks (Archive 2016.11) March 17, 2017 Newsfeed: PD News PD Research News PD Fitness News PD Boxing News PD Web Articles PD Blogs PD Editor's Picks PD Twitter Newsfeed Neurons Paralyze Us During REM SleepIt will also be most useful in the study of Parkinson’s disease, since these pathologies are related. This work was published on December 12, 2016 on the website of the journal Brain.…
- CHMP Favors EU Approval of Inbrija to Treat Parkinson’s Off Periods July 29, 2019 The Committee for Medicinal Products for Human Use (CHMP) — an arm of the European Medicines Agency (EMA) — is recommending that Inbrija, by Acorda Therapeutics, be approved to treat off periods in Parkinson’s patients on a carbidopa/levodopa regimen. The European Commission will review CHMP’s positive opinion, with a decision expected before year’s end. “We are delighted that Inbrija has achieved this…
- Monthly Research Review – September 2019 September 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Additional Blood Cell Monitoring Added to Tozadenant Trials Following Adverse Events November 20, 2017 Acorda Therapeutics announced that it will now monitor blood cell counts on a weekly basis in Parkinson’s disease patients enrolled in the company’s Phase 3 program investigating the safety and effectiveness of tozadenant. The update to the clinical trial responds to cases of patients developing agranulocytosis, a severe drop in white blood cells that are vital to fighting infections. The cases…
- Acorda to Present Data at the International Congress of Parkinson's Disease and Movement Disorders - BioSpace September 18, 2019 Acorda to Present Data at the International Congress of Parkinson's Disease and Movement Disorders BioSpaceARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present data at the International Congress of ...
- New Art Initiative Aims to Improve Understanding and Discussion of Parkinson’s Off Periods December 18, 2018 A new initiative by Acorda Therapeutics uses art to help people with Parkinson’s disease recognize and communicate about their off-period experiences. The initiative, called Framing OFF Through Art, builds on Acorda’s Live Well. Do Tell program, launched earlier this year. Framing OFF Through Art includes artwork inspired by the experiences of patients with Parkinson’s and their caregivers. The artists who created the pieces…
- New Art Initiative Aims to Improve Understanding and Discussion of Parkinson’s Off Periods December 18, 2018 A new initiative by Acorda Therapeutics uses art to help people with Parkinson’s disease recognize and communicate about their off-period experiences. The initiative, called Framing OFF Through Art, builds on Acorda’s Live Well. Do Tell program, launched earlier this year. Framing OFF Through Art includes artwork inspired by the experiences of patients with Parkinson’s and their caregivers. The artists who created the pieces…
- Inbrija Can Help to Improve Work Productivity and Keep Dyskinesia at Bay, Acorda Reports September 23, 2019 Use of Inbrija (levodopa inhalation powder) and like medications help to more effectively manage of off episodes in Parkinson’s disease and improve work productivity in patients taking it, according to a study being presented by Acorda Therapeutics at the International Congress of Parkinson’s Disease and Movement Disorders. Another study presentation at the congress, now underway in France, will show that…